Page last updated: 2024-11-04

1,3-diethyl-8-phenylxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-diethyl-8-phenylxanthine, also known as 8-phenyltheophylline, is a synthetic derivative of theophylline. It is a selective adenosine receptor antagonist, with high affinity for the A1 receptor subtype. The compound exhibits pharmacological effects such as bronchodilation, cardiovascular stimulation, and central nervous system stimulation. It has been studied for its potential therapeutic use in the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. Its synthesis involves the alkylation of theophylline with ethyl bromide, followed by the coupling of the resulting intermediate with phenylmagnesium bromide.'

1,3-diethyl-8-phenylxanthine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1328
CHEMBL ID11348
SCHEMBL ID1321894
MeSH IDM0089358

Synonyms (39)

Synonym
gtpl445
EU-0100125
NCGC00014999-01
lopac-a-003
PDSP1_000323
PDSP2_000321
PDSP1_000991
LOPAC0_000125
PDSP1_000326
PDSP2_000324
PDSP2_000975
NCGC00093616-01
1,3-diethyl-8-phenylxanthine
depx
NCGC00014999-02
A-003
L001207
CHEMBL11348 ,
75922-48-4
1,3-diethyl-8-phenyl-7h-purine-2,6-dione
cas_1328
1,3-diethyl-8-phenyl-3,7-dihydro-purine-2,6-dione
nsc_1328
bdbm81971
SCHEMBL1321894
CCG-204220
1h-purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-phenyl-
2kcv39gkgl ,
unii-2kcv39gkgl
8-phenyl-1,3-diethylxanthine
FT-0606658
1h-purine-2,6-dione, 1,3-diethyl-3,9-dihydro-8-phenyl-
1,3-dithyl-8-phenylxanthine
AKOS027378654
SR-01000075182-1
sr-01000075182
1,3-diethyl-8-phenyl-1h-purine-2,6(3h,7h)-dione
Q27077019
DTXSID80877797

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Under the same treatment conditions, caffeine became a more potent antagonist of PIA-induced analgesia, and the dose-response curve for the locomotor effects of caffeine was shifted to the left."( Changes in adenosine receptor sensitivity in morphine-tolerant and -dependent mice.
Ahlijanian, MK; Takemori, AE, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency18.96620.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency18.96620.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency44.66845.623417.292931.6228AID2323
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency37.933023.934123.934123.9341AID1967
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.15850.039816.784239.8107AID995
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.98110.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.44670.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.04000.00020.552110.0000AID31397; AID31399
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.04450.00011.20929.9700AID32500
Adenosine receptor A1Bos taurus (cattle)IC50 (µMol)1,509,975.00150.00001.09106.7400AID31836; AID31838
Adenosine receptor A2bHomo sapiens (human)Ki0.06200.00021.635210.0000AID33176
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.83600.00061.353610.0000AID33728
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.83600.00021.494010.0000AID33728
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)Kb0.21000.00131.08292.7000AID30635
Adenosine receptor A2bHomo sapiens (human)Kb0.21000.00601.08342.7000AID30635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Bos taurus (cattle)
response to purine-containing compoundAdenosine receptor A1Bos taurus (cattle)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID232222Selectivity for A2 and A1 receptors was evaluated1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.
AID31838Log IC50 value was determined against adenosine A1 receptor in bovine brain membranes1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID25618Equilibrium constant (pKa) was determined.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID23563Solubility in 0.1 N HCl1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID31399Binding affinity towards adenosine A1 receptor of rat brain membranes with 1 M NaCl by inhibition of [125-I]-labeled aminobenzyl adenosine binding 1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors.
AID33435Binding affinity against Adenosine A2 receptor in rat brain membrane, using [3H]-NECA as the radioligand.1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.
AID30635Antagonism of NECA-induced stimulation of adenylate cyclase activity in human platelet membranes at A2-adenosine receptor1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Xanthine functionalized congeners as potent ligands at A2-adenosine receptors.
AID31836Binding affinity against bovine brain adenosine A1 receptor by using N6-[3H]- cyclohexyladenosine1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID23562Solubility in 0.1 M phosphate buffer at pH 7.41985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID54313log(1000/IC50 determined from bovine brain membrane) expressed as potency1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID31861Binding affinity against Adenosine A1 receptor in rat brain membrane, using [3H]N6-cyclohexyladenosine as the radioligand1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.
AID31397Binding affinity to adenosine A1 receptor of rat brain membranes without NaCl by inhibition of [125-I]-labeled aminobenzyl adenosine binding1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors.
AID32500Inhibition of binding of 1 nM [3H]N-6-(phenylisopropyl)adenosine to adenosine A1 receptor in rat cortical membranes1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.
AID33728Inhibition of binding of [3H]5'-(N-ethylcarbamoyl)-adenosine to adenosine A2 receptor in rat striatal membranes1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.
AID23491Partition coefficient (logP)1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID30335Log IC50 value was determined against adenosine A1 receptor in rat brain membranes1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.
AID230229Inhibitory selectivity for A2 receptor in rat striatal membranes and A1 receptor in rat cortical membranes1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.
AID33176Binding affinity at human Adenosine A2B receptor expressed in HEK293 cells, using [125I]ABOPX as radioligand2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
AID32495Inhibition of [3H]- PIA binding at adenosine A1 receptor on rat cerebral cortex membranes.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Xanthine functionalized congeners as potent ligands at A2-adenosine receptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345721Human A2B receptor (Adenosine receptors)1999Molecular pharmacology, Oct, Volume: 56, Issue:4
Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (80.00)18.7374
1990's3 (8.57)18.2507
2000's3 (8.57)29.6817
2010's1 (2.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.51 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]